A study published in The Lancet Planetary Health reveals that tropical mosquito-borne diseases such as dengue and chikungunya ...

The CDC’s restricted communication under HHS oversight has hindered public awareness amid rising global disease outbreaks ...

The FDA and CDC are recommending a pause on the use of Ixchiq (chikungunya vaccine, live) in patients 60 years and older during an ongoing safety investigation.

The U.S. Centers for Disease Control and Prevention accepted its advisory panel's recommendations on vaccines for chikungunya ...

The U.S. Centers for Disease Control and Prevention has accepted its advisory panel's recommendations on vaccines for ...

Mosquitoes can tranmist dengue virus, which has already caused local cases in Florida in 2025... | Clinical And Molecular Dx ...

The approval applies to anyone aged 18 and older who has a risk of being exposed to the virus. But the FDA and the Centers ...

US health officials are telling travelers aged 60 and older to avoid a chikungunya vaccine while they investigate possible side effects.

Chikungunya isn't prevalent in the U.S., but travelers are being told to be cautious about getting the vaccine for the ...

Early COVID suppression could have prevented 180,000 UK deaths, study reveals … FDA, CDC pause chikungunya vaccine for adults ...

A vaccine designed to protect against chikungunya, a mosquito-borne illness, has been temporarily paused for individuals aged 60 and older.

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.